Memorial Sloan Kettering provides roadmap for successful CAR-T cell program

An article from the Memorial Sloan Kettering Cancer Center (MSK) analyzes what it identifies as the key dimensions of a successful CAR-T cell therapy development program.

The novel approach in immuno-oncology uses gene transfer technology to modify an individual patient’s own T-cells, a type of white blood cell that is of key importance to the immune system.

Published in Biology of Blood and Marrow Transplantations, the article looks at the clinical, administrative, and regulatory challenges for the successful implementation of any such program.